Shots:
- The Chinese NMPA has accepted the BLA & granted priority review to Opamtistomig (LBL-024) as a monotx. for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC)
- BLA was supported by the registrational trial data, designed to assess the efficacy & safety of Opamtistomig in pts with advanced EP-NEC whose disease had progressed following ≥2 prior lines of systemic therapy
- Opamtistomig is a next-generation PD-L1/4-1BB bispecific antibody, developed on Leads’ X-Body platform, designed to block PD-1/L1 signaling & conditionally activate 4-1BB to enhance anti-tumor immunity, with potential OS benefit across multiple cancers
Ref: PRnewswire | Image: Nanjing Leads Biolabs | Press Release
Related News: Nanjing Leads Biolabs Reports First Patient Enrolment in P-Ib/II Trial of Opatisumab for Advanced Melanoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
